PATENT ASSIGNMENT AND LICENSE AGREEMENT September 27, 2016Patent Assignment and License Agreement • October 3rd, 2016 • Donnelley Financial Solutions, Inc. • Services-miscellaneous business services • Illinois
Contract Type FiledOctober 3rd, 2016 Company Industry JurisdictionThis PATENT ASSIGNMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of September 30, 2016 (the “Effective Date”), by and between R. R. Donnelley & Sons Company, a Delaware corporation (“RRD”), and Donnelley Financial, LLC, a limited liability company (“DFS”). Each of RRD and DFS is referred to herein as a “Party” and collectively as the “Parties.”
RECITALS --------Patent Assignment and License Agreement • February 12th, 2002 • Surgilight Inc • Blank checks • California
Contract Type FiledFebruary 12th, 2002 Company Industry Jurisdiction
ContractPatent Assignment and License Agreement • May 27th, 2004 • Orchid Biosciences Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledMay 27th, 2004 Company Industry JurisdictionORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
PATENT ASSIGNMENT AND LICENSE AGREEMENTPatent Assignment and License Agreement • July 3rd, 2014 • Trovagene, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJuly 3rd, 2014 Company Industry JurisdictionThis Patent Assignment and License Agreement (hereinafter the “Agreement”), effective as of April 23, 2014 (the “Effective Date”), is entered by and between:
EX-10.1 2 dex101.htm PATENT ASSIGNMENT AND LICENSE AGREEMENT, DATED MAY 21, 2008 EXECUTION COPYPatent Assignment and License Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis PATENT ASSIGNMENT AND LICENSE AGREEMENT, dated May 21, 2008 (“Effective Date”), is entered into by and between Ribotask ApS, having its offices at Søndre Boulevard 44, 3, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and Nastech Pharmaceutical Company Inc., having its offices at 3830 Monte Villa Parkway, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
AMENDED AND RESTATED PATENT ASSIGNMENT AND LICENSE AGREEMENT BY AND BETWEEN SemiLEDs Corporation AND Xurui Guangdian Co., Ltd. ON July 19, 2010Patent Assignment and License Agreement • October 6th, 2010 • SemiLEDs Corp • Semiconductors & related devices
Contract Type FiledOctober 6th, 2010 Company IndustrySemiLEDs Corporation, an American corporation incorporated and existing under the laws of USA, with registered office at 999 Main Street, Suite 1010, Boise, ID83702, USA and duly represented by Trung Tri Doan (nationality: USA) (hereinafter referred to as “Assignor”); and
ContractPatent Assignment and License Agreement • August 12th, 2010 • Marina Biotech, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 12th, 2010 Company IndustryAmendment No. 3, dated as of the 4th day of June, 2010 (“Amendment No. 3”), to a certain Patent Assignment And License Agreement, dated May 21, 2008, as amended and/or supplemented by Amendment No. 1 dated October 9, 2008, Patent Assignment dated November 3, 2008, and Amendment No. 2 dated June 18, 2009 (collectively, the “Agreement”), by and between Ribotask ApS, having its offices at Unsbjergvej 2A, 5220 Odense SØ, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] PATENT ASSIGNMENT AND LICENSE AGREEMENTPatent Assignment and License Agreement • February 14th, 2023 • Insulet Corp • Surgical & medical instruments & apparatus • Delaware
Contract Type FiledFebruary 14th, 2023 Company Industry JurisdictionThis Patent Assignment and License Agreement (this “Agreement”, as further defined below) is made and entered into as of this 9th day of February, 2023 (the “Effective Date”), by and between Insulet Corporation, a Delaware corporation, with an address at 100 Nagog Park, Acton, MA 01720 (“Insulet”), Bigfoot Biomedical, Inc., a Delaware corporation with an address at 1820 McCarthy Blvd., Milpitas, CA 95035, and Patients Pending, Ltd., a company registered under the laws of England (No. 07382438) and wholly-owned subsidiary of Bigfoot Biomedical, Inc., having an address at 20-22 Wenlock Road, London N1 7GU, England (Bigfoot Biomedical, Inc. and Patients Pending, Ltd. collectively, “Bigfoot”). Insulet and Bigfoot may be referred to herein individually as a “Party” and collectively as the “Parties.”
ContractPatent Assignment and License Agreement • August 14th, 2003 • Cell Genesys Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 14th, 2003 Company Industry JurisdictionNOTE: Information in this document marked with an "[*]" has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractPatent Assignment and License Agreement • August 12th, 2010 • Marina Biotech, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 12th, 2010 Company IndustryAmendment No. 2, dated June 18, 2009 (“Amendment No. 2”), to a certain Patent Assignment And License Agreement, dated May 21, 2008, as amended October 9, 2008 (the “Agreement”), by and between Ribotask ApS, having its offices at Promenadebyen 2, 8. sal, lejl. 4, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).
Exhibit 10.1Patent Assignment and License Agreement • June 3rd, 2002 • Surgilight Inc • Electromedical & electrotherapeutic apparatus • California
Contract Type FiledJune 3rd, 2002 Company Industry Jurisdiction
PATENT ASSIGNMENT AND LICENSE AGREEMENTPatent Assignment and License Agreement • August 8th, 2016 • Donnelley Financial Solutions, Inc. • Services-miscellaneous business services • Illinois
Contract Type FiledAugust 8th, 2016 Company Industry JurisdictionThis PATENT ASSIGNMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of the Donnelley Financial Distribution Date (as defined below), by and between R. R. Donnelley & Sons Company, a Delaware corporation (“RRD”), and Donnelley Financial, LLC, a limited liability company (“DFS”). Each of RRD and DFS is referred to herein as a “Party” and collectively as the “Parties.”
PATENT ASSIGNMENT AND LICENSE AGREEMENTPatent Assignment and License Agreement • July 30th, 2024 • Delaware
Contract Type FiledJuly 30th, 2024 JurisdictionThis Patent Assignment and License Agreement (“Agreement”), dated as of [⚫], 2024 (the “Effective Date”), is by and between Sirnaomics, Inc., a Delaware corporation, with offices located at 20511 Seneca Meadows Parkway, Suite 200, Germantown, MD 20876 USA (“Sirnaomics”), and Sagesse Bio, Inc., a Delaware corporation, with offices located at 5313 Shadow Glen Dr., Grapevine, TX 76051 USA (“Sagesse”) (collectively, the “Parties,” or each, individually, a “Party”).
Patent assignment and license agreementPatent Assignment and License Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
Contract Type FiledMay 14th, 2018 Company Industry JurisdictionThis PATENT ASSIGNMENT AND LICENSE AGREEMENT, dated August 9, 2013 (“Effective Date”), is entered into by and between Marina Biotech, Inc., a Delaware corporation (“Assignor”), and Arcturus Therapeutics, Inc., a Delaware corporation (“Assignee”).
ContractPatent Assignment and License Agreement • August 12th, 2010 • Marina Biotech, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 12th, 2010 Company IndustryAmendment No. 1, dated October 9, 2008, to a certain Patent Assignment And License Agreement, dated May 21, 2008 (the “Agreement”), by and between Ribotask ApS, having its offices at Søndre Boulevard 44, 3, 5000 Odense C, Denmark, being a corporation established under the laws of Denmark (“Assignor”), and MDRNA, Inc. (f/k/a Nastech Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (“Assignee”).